4:55 PM
 | 
Aug 27, 2013
 |  BC Extra  |  Clinical News

Roche reports Phase II dry AMD data

Roche (SIX:ROG; OTCQX:RHHBY) said monthly lampalizumab ( RG7417) met the primary endpoint of reducing geographic atrophy (GA) area from baseline to month 18 vs. sham...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >